U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H30Cl2N10
Molecular Weight 505.447
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHLORHEXIDINE

SMILES

ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1

InChI

InChIKey=GHXZTYHSJHQHIJ-UHFFFAOYSA-N
InChI=1S/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34)

HIDE SMILES / InChI

Molecular Formula C22H30Cl2N10
Molecular Weight 505.447
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019028s022lbl.pdf http://www.drugbank.ca/drugs/DB00878 http://www.wikidoc.org/index.php/Chlorhexidine_gluconate

Chlorhexidine is a broad-spectrum biocide effective against Gram-positive bacteria, Gram-negative bacteria and fungi. It is used primarily as its salts (e.g., the dihydrochloride, diacetate, and digluconate). Chlorhexidine inactivates microorganisms with a broader spectrum than other antimicrobials (e.g. antibiotics) and has a quicker kill rate than other antimicrobials (e.g. povidone-iodine). It has both bacteriostatic (inhibits bacterial growth) and bactericidal (kills bacteria) mechanisms of action, depending on its concentration. Chlorhexidine kills by disrupting the cell membrane. The most common side effects associated with chlorhexidine gluconate oral rinses are: 1) an increase in staining of teeth and other oral surfaces; 2) an increase in calculus formation; and 3) an alteration in taste perception; 4) toothache; 5) upper respiratory tract infection; and 6) headache.

Originator

Curator's Comment: 1950s — Chlorhexidine is discovered by the Imperial Chemical Industries, Limited (Manchester, UK) while researching the synthesis of anti-malarial agents

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
HIBICLENS

Approved Use

Use for the preparation of the patient's skin prior to surgery. Helps to reduce bacteria that potentially can cause skin infection.

Launch Date

2.11766395E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2007 μg/mL
2.5 mg single, dental
dose: 2.5 mg
route of administration: Dental
experiment type: SINGLE
co-administered:
CHLORHEXIDINE inflammatory exudate
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.206 μg/g
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORHEXIDINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
187083.4 μg × h/mL
2.5 mg single, dental
dose: 2.5 mg
route of administration: Dental
experiment type: SINGLE
co-administered:
CHLORHEXIDINE inflammatory exudate
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
148287.6 ng × h/mL
0.2 % single, dental
dose: 0.2 %
route of administration: Dental
experiment type: SINGLE
co-administered:
CHLORHEXIDINE saliva
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
180892.9 ng × h/mL
0.2 % 1 times / day multiple, dental
dose: 0.2 %
route of administration: Dental
experiment type: MULTIPLE
co-administered:
CHLORHEXIDINE saliva
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
17%
CHLORHEXIDINE serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
73%
CHLORHEXIDINE saliva
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 % 1 times / day single, topical
Recommended
Dose: 2 %, 1 times / day
Route: topical
Route: single
Dose: 2 %, 1 times / day
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 18-64 years
n = 36
Health Status: healthy
Age Group: 18-64 years
Sex: M+F
Population Size: 36
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
Other AEs: Redness...
Other AEs:
Redness (grade 2)
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
3 % 1 times / day multiple, topical (mean)
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 18-79 years
n = 204
Health Status: healthy
Age Group: 18-79 years
Sex: M+F
Population Size: 204
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
Disc. AE: Papule, Erythema...
AEs leading to
discontinuation/dose reduction:
Papule
Erythema (grade 2)
Edema (grade 1)
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
3 % 1 times / day multiple, topical (mean)
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 22-60 years
n = 23
Health Status: healthy
Age Group: 22-60 years
Sex: M+F
Population Size: 23
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
Disc. AE: Burning sensation, Petechial rash...
AEs leading to
discontinuation/dose reduction:
Burning sensation (grade 1)
Petechial rash (grade 1)
Scab
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
1.5 oz 1 times / day single, oral (mean)
Studied dose
Dose: 1.5 oz, 1 times / day
Route: oral
Route: single
Dose: 1.5 oz, 1 times / day
Sources:
healthy, child
n = 1
Health Status: healthy
Age Group: child
Population Size: 1
Sources:
Other AEs: Distress epigastric, Nausea...
Other AEs:
Distress epigastric
Nausea
Alcohol intoxication
Sources:
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Other AEs: Toothache, Upper respiratory tract infection...
Other AEs:
Toothache (50.7%)
Upper respiratory tract infection (28.4%)
Headache (27.1%)
Sinusitis (13.8%)
Influenza-like symptoms (7.6%)
Back pain (6.7%)
Tooth disorder (6.2%)
Bronchitis (6.2%)
Abscess (5.8%)
Pain (4.9%)
Allergy (4%)
Myalgia (4%)
Gum hyperplasia (3.6%)
Pharyngitis (3.6%)
Arthralgia (3.1%)
Dysmenorrhea (3.1%)
Dyspepsia (3.1%)
Rhinitis (2.7%)
Coughing (2.7%)
Arthrosis (2.7%)
Hypertension (2.2%)
Stomatitis ulcerative (2.2%)
Tendinitis (2.2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Redness grade 2
2 % 1 times / day single, topical
Recommended
Dose: 2 %, 1 times / day
Route: topical
Route: single
Dose: 2 %, 1 times / day
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 18-64 years
n = 36
Health Status: healthy
Age Group: 18-64 years
Sex: M+F
Population Size: 36
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
Papule Disc. AE
3 % 1 times / day multiple, topical (mean)
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 18-79 years
n = 204
Health Status: healthy
Age Group: 18-79 years
Sex: M+F
Population Size: 204
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
Edema grade 1
Disc. AE
3 % 1 times / day multiple, topical (mean)
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 18-79 years
n = 204
Health Status: healthy
Age Group: 18-79 years
Sex: M+F
Population Size: 204
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
Erythema grade 2
Disc. AE
3 % 1 times / day multiple, topical (mean)
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 18-79 years
n = 204
Health Status: healthy
Age Group: 18-79 years
Sex: M+F
Population Size: 204
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
Scab Disc. AE
3 % 1 times / day multiple, topical (mean)
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 22-60 years
n = 23
Health Status: healthy
Age Group: 22-60 years
Sex: M+F
Population Size: 23
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
Burning sensation grade 1
Disc. AE
3 % 1 times / day multiple, topical (mean)
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 22-60 years
n = 23
Health Status: healthy
Age Group: 22-60 years
Sex: M+F
Population Size: 23
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
Petechial rash grade 1
Disc. AE
3 % 1 times / day multiple, topical (mean)
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 22-60 years
n = 23
Health Status: healthy
Age Group: 22-60 years
Sex: M+F
Population Size: 23
Sources: Page: nda/2005/21669s000_MedR.pdf - p.83
Alcohol intoxication
1.5 oz 1 times / day single, oral (mean)
Studied dose
Dose: 1.5 oz, 1 times / day
Route: oral
Route: single
Dose: 1.5 oz, 1 times / day
Sources:
healthy, child
n = 1
Health Status: healthy
Age Group: child
Population Size: 1
Sources:
Distress epigastric
1.5 oz 1 times / day single, oral (mean)
Studied dose
Dose: 1.5 oz, 1 times / day
Route: oral
Route: single
Dose: 1.5 oz, 1 times / day
Sources:
healthy, child
n = 1
Health Status: healthy
Age Group: child
Population Size: 1
Sources:
Nausea
1.5 oz 1 times / day single, oral (mean)
Studied dose
Dose: 1.5 oz, 1 times / day
Route: oral
Route: single
Dose: 1.5 oz, 1 times / day
Sources:
healthy, child
n = 1
Health Status: healthy
Age Group: child
Population Size: 1
Sources:
Sinusitis 13.8%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Hypertension 2.2%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Stomatitis ulcerative 2.2%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Tendinitis 2.2%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Arthrosis 2.7%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Coughing 2.7%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Rhinitis 2.7%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Headache 27.1%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Upper respiratory tract infection 28.4%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Arthralgia 3.1%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Dysmenorrhea 3.1%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Dyspepsia 3.1%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Gum hyperplasia 3.6%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Pharyngitis 3.6%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Allergy 4%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Myalgia 4%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Pain 4.9%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Abscess 5.8%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Toothache 50.7%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Bronchitis 6.2%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Tooth disorder 6.2%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Back pain 6.7%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
Influenza-like symptoms 7.6%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
n = 225
PubMed

PubMed

TitleDatePubMed
The effect of chlorhexidine irrigation of the bladder in the rat.
1975 Oct
Further studies on effects of irrigation solutions on rat bladders.
1976 Dec
Nephrotoxic and hepatotoxic effects of triclosan and chlorhexidine in rats.
1977 Oct
Some toxic effects of lead, other metals and antibacterial agents on the nervous system--animal experiment models.
1984
Bradycardia associated with chlorhexidine spray.
1989 Jun
Effects of chlorhexidine diacetate on Candida albicans, C. glabrata and Saccharomyces cerevisiae.
1992 Apr
[Anaphylactic shock with ventricular fibrillation induced by chlorhexidine].
1992 Mar
The activity of candidate virucidal agents, low pH and genital secretions against HIV-1 in vitro.
1995 Jul-Aug
Clinical and pathological changes in the knee after accidental chlorhexidine irrigation during arthroscopy. Case reports and review of the literature.
1998 May
6-month use of 0.2% delmopinol hydrochloride in comparison with 0.2% chlorhexidine digluconate and placebo. (I). Effect on plaque formation and gingivitis.
1998 Sep
Probing depth changes following 2 years of periodontal maintenance therapy including adjunctive controlled release of chlorhexidine.
2003 Apr
Effects of a chlorhexidine gluconate-containing mouthwash on the vitality and antimicrobial susceptibility of in vitro oral bacterial ecosystems.
2003 Aug
[Contact sensitization to pharmaceutic aids in dermatologic cosmetic and external use preparations].
2004 May
Chlorhexidine induces DNA damage in rat peripheral leukocytes and oral mucosal cells.
2004 Oct
Short-term side effects of 0.2% alcohol-free chlorhexidine mouthrinse used as an adjunct to non-surgical periodontal treatment: a double-blind clinical study.
2006 Mar
[Ultrastructure study of pathogen of acanthamoeba keratitis].
2008 Nov
Chlorhexidine-induced apoptosis or necrosis in L929 fibroblasts: A role for endoplasmic reticulum stress.
2009 Jan 15
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Food components with anticaries activity.
2012 Apr
Cytotoxicity and genotoxicity of chlorhexidine on macrophages in vitro.
2014 Apr
Patents

Sample Use Guides

Recommended use is twice daily oral rinsing for 30 seconds, morning and evening after tooth brushing. Usual dosage is 15 ml (1 tablespoon) of undiluted Chlorhexidine gluconate oral rinse. Prophylaxis intervals - no longer than six months.
Route of Administration: Topical
In Vitro Use Guide
Curator's Comment: Chlorhexidine caused significant decreases in both total anaerobe and total aerobe/facultative anaerobe counts (P < 0.05), together with lesser decreases in gram-negative anaerobes.
Minimum bactericidal concentrations are different for different bacterial strains (3.9-83.3 mg/l).
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:08:58 UTC 2023
Edited
by admin
on Sat Dec 16 17:08:58 UTC 2023
Record UNII
R4KO0DY52L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHLORHEXIDINE
HSDB   INCI   INN   MART.   MI   USP-RS   VANDF   WHO-DD  
INN   INCI  
Official Name English
Chlorhexidine [WHO-DD]
Common Name English
CHLORHEXIDINE [INCI]
Common Name English
MERFEN-INCOLORE
Brand Name English
CHLORHEXIDINE [HSDB]
Common Name English
CHLORHEXIDINE [VANDF]
Common Name English
CHLORHEXADINE
Common Name English
CHLORHEXIDINE [MI]
Common Name English
DENTISEPT
Brand Name English
CHLORHEXIDINE [USP-RS]
Common Name English
CHLORHEXIDINE [MART.]
Common Name English
chlorhexidine [INN]
Common Name English
Classification Tree Code System Code
WHO-ATC D08AC02
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
WHO-ATC S02AA09
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
WHO-ATC A01AB03
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
WHO-VATC QA01AB03
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
WHO-ATC S03AA04
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
WHO-VATC QD08AC02
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
WHO-VATC QD08AC52
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
NCI_THESAURUS C28394
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
CFR 21 CFR 524.402
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
WHO-ATC R02AA05
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
WHO-VATC QR02AA05
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
CFR 21 CFR 556.120
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
WHO-VATC QS03AA04
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
WHO-VATC QD09AA12
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
WHO-VATC QS01AX09
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
NDF-RT N0000008478
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
WHO-ATC S01AX09
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
WHO-ATC D08AC52
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
WHO-ATC D09AA12
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 15.1
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
WHO-VATC QS02AA09
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
WHO-VATC QB05CA02
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
WHO-ATC B05CA02
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
EPA PESTICIDE CODE 217100
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
Code System Code Type Description
DRUG BANK
DB00878
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-238-7
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY
MERCK INDEX
m3362
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY Merck Index
DRUG CENTRAL
597
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY
EVMPD
SUB06181MIG
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY
MESH
D002710
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY
NCI_THESAURUS
C364
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY
PUBCHEM
2713
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY
FDA UNII
R4KO0DY52L
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY
HSDB
7196
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY
CHEBI
3614
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY
CAS
55-56-1
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY
WIKIPEDIA
CHLORHEXIDINE
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY
EPA CompTox
DTXSID2033314
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY
INN
500
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY
ChEMBL
CHEMBL790
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY
RS_ITEM_NUM
1111001
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY
RXCUI
2358
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY RxNorm
DAILYMED
R4KO0DY52L
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY
SMS_ID
100000081581
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY
LACTMED
Chlorhexidine
Created by admin on Sat Dec 16 17:09:00 UTC 2023 , Edited by admin on Sat Dec 16 17:09:00 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY